Post-treatment response following 48 weeks of lonafarnib therapy: analysis of 24-weekfollow-up in the phase 3D-LIVRtrial in chronic hepatitis delta
The durability of treatment response following therapy cessation remains an important consideration in the management of chronic hepatitis D virus (HDV) infection, especially as approved HDV therapies cannot currently be safely stopped.
Clinical significance of ALT dynamics following lonafarnib treatment cessation in the phase 3 D-LIVR trial
Alanine aminotransferase (ALT) elevations have been reported following treatment discontinuation of currently-available chronic hepatitis D virus (HDV) and hepatitis B (HBV) treatments, but their clinical significance remains uncertain.
Histologic improvement and reduction in necroinflammation with lonafarnib-based therapy in chronic hepatitis delta: phase 3 D-LIVR trial
Direct assessment of liver tissue health through collection of paired biopsies is key to distinguishing true antiviral efficacy from fluctuations in biomarkers.
Histologic improvement and reduction in necroinflammation with lonafarnib-based therapy in chronic hepatitis delta: phase 3 D-LIVR trial
By inhibiting farnesyltransferase, lonafarnib (LNF) disrupts HDV virion assembly in infected hepatocytes and promotes immune modulation.
Lonafarnib for chronic hepatitis delta
Clinical mechanism of action, development, and evolving role in combination therapy
Lonafarnib/ritonavir and peg-interferon alfa drive histological improvement and inflammation resolution in chronic HDV
Results of the multicenter phase 3 D-LIVR study
Lonafarnib/ritonavir with or without peginterferon achieves rapid, durable responses in a chronic hepatitis D:
Extended analyses from the phase 3 D-LIVR trial